Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors

Trial Profile

Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Anal cancer; Biliary cancer; Carcinoid tumour; Carcinoma; Cervical cancer; Endometrial cancer; Mesothelioma; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Biomarker; Proof of concept; Registrational; Therapeutic Use
  • Acronyms KEYNOTE-028; MK-3475-028/KEYNOTE-28
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Jun 2019 According to a Merck & Co media release, the U.S. Food and Drug Administration (FDA) has approved (accelerated approval) KEYTRUDA, as monotherapy for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. The approval was based on pooled data from KEYNOTE-158 (cohort G) and KEYNOTE-028 (cohort C1) studies.
    • 04 Jun 2019 Follow-up data from patients with advanced biliary tract cancer treated with pembrolizumab in the KN158 (NCT02628067; phase 2) and KN028 (NCT02054806; phase 1) basket studies; results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 01 Apr 2019 According to a Merck & Co media release, pooled data from the KEYNOTE-158 and KEYNOTE-028 trials was presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top